Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

MLA

Lee S Nguyen, et al. “Reversal of Immune-Checkpoint Inhibitor Fulminant Myocarditis Using Personalized-Dose-Adjusted Abatacept and Ruxolitinib: Proof of Concept.” Journal for ImmunoTherapy of Cancer, vol. 10, Apr. 2022, p. e004699. EBSCOhost, https://doi.org/10.1136/jitc-2022-004699.

APA

Lee S Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, Baptiste Abbar, Bruno Pinna, Yves Allenbach, Jean-Paul Mira, Javid Moslehi, Michelle Rosenzwajg, & Joe-Elie Salem. (2022). Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for ImmunoTherapy of Cancer, 10, e004699. https://doi.org/10.1136/jitc-2022-004699

Chicago

Lee S Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, Baptiste Abbar, Bruno Pinna, et al. 2022. “Reversal of Immune-Checkpoint Inhibitor Fulminant Myocarditis Using Personalized-Dose-Adjusted Abatacept and Ruxolitinib: Proof of Concept.” Journal for ImmunoTherapy of Cancer 10 (April): e004699. doi:10.1136/jitc-2022-004699.